Quantum Biopharma (QNTM) Change in Receivables (2020 - 2026)
Quantum Biopharma (QNTM) posted Change in Receivables of $22529.0 for Q1 2026, up 122.6% sequentially from -$99701.0 in Q4 2025, and down 77.34% YoY from $99417.0 in Q1 2025.
Quantum Biopharma (QNTM) Change in Receivables (2020 - 2026) Analysis & Trends
Quantum Biopharma has reported Change in Receivables for 7 years, with the latest figure at $22529.0 in Q1 2026.
- Quarterly Change in Receivables fell 77.34% year-over-year to $22529.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119789.0 (up 210.21% YoY) and the FY2025 annual result came in at $196677.0, up 234.79% from the prior year.
- Change in Receivables improved to $22529.0 in Q1 2026 per QNTM's latest filing, from -$99701.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $626939.0 in Q3 2022 and troughed at -$532562.0 in Q2 2022.
- A 5-year average of $26356.0 and a median of $56024.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables slumped 1758.42% in 2024, then surged 762.77% in 2025.
- Over 5 years, Change in Receivables stood at -$49813.0 in 2022, then soared by 70.78% to -$14554.0 in 2023, then plunged by 1758.42% to -$270474.0 in 2024, then soared by 63.14% to -$99701.0 in 2025, then surged by 122.6% to $22529.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $22529.0, -$99701.0, and $114898.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | 100,890.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,890.00 |
| Jun 30, 2026 | 100,890.00 |
| Mar 31, 2026 | 22,529.00 |
| Mar 31, 2026 | 22,529.00 |
| Dec 31, 2025 | -99,701.00 |
| Dec 31, 2025 | -99,701.00 |
| Sep 30, 2025 | 114,898.00 |
| Sep 30, 2025 | 114,898.00 |
| Jun 30, 2025 | 82,063.00 |
| Jun 30, 2025 | 82,063.00 |
| Mar 31, 2025 | 99,417.00 |
| Mar 31, 2025 | 99,417.00 |
| Dec 31, 2024 | -270,474.00 |
| Dec 31, 2024 | -270,474.00 |
| Sep 30, 2024 | -17,336.00 |
| Sep 30, 2024 | -17,336.00 |
| Jun 30, 2024 | 79,700.00 |
| Jun 30, 2024 | 79,700.00 |
| Mar 31, 2024 | 62,196.00 |
| Mar 31, 2024 | 62,196.00 |